MedTech companies dedicate tremendous efforts to demonstrate safety and efficacy of their new technologies to achieve regulatory approval and convince physicians of the value of their innovation. Unfortunately, many companies struggle to win proper coverage, coding and payment for new technologies.
Payers focus on different questions, assuming that safety and efficacy have been already established by the regulatory authorities. Payers assess new technologies with the aim to understand the benefit for the patients and for the healthcare system as a whole. In addition to clinical effectiveness, health economic arguments are often being requested for new technologies. Understanding market access pathways and integrating payers’ considerations early into clinical development programs can help maximizing the return on your clinical investments and speed up the time to reimbursement.
In this webinar, Brigitte Casteels, Executive Advisor, Cytel and Natasha Mühlemann, VP Strategic Consulting, Cytel, will review the reimbursement landscape and market access strategies for medical device and discuss how to integrate market access considerations into clinical development programs.